Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells

被引:0
作者
Huibo Li
Xiaolin Kong
Gang Cui
Cuicui Ren
Shengjin Fan
Lili Sun
Yingjie Zhang
Rongyi Cao
Yinghua Li
Jin Zhou
机构
[1] Harbin Medical University,Division of Hematology, Department of Medicine, The First Affiliated Hospital
来源
International Journal of Hematology | 2015年 / 102卷
关键词
Acute lymphoblastic leukemia; Rapamycin; p14; p15; p57; mTOR;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study was to investigate the effects of rapamycin and its underlying mechanisms on acute lymphoblastic leukemia (ALL) cells. We found that the p14, p15, and p57 genes were not expressed in ALL cell lines (Molt-4 and Nalm-6) and adult ALL patients, whereas mTOR, 4E-BP1, and p70S6K were highly expressed. In Molt-4 and Nalm-6 cells exposed to rapamycin, cell viability decreased and the cell cycle was arrested at the G1/S phase. Rapamycin restored p14, p15, and p57 gene expression through demethylation of the promoters of these genes. As expected, rapamycin also increased p14 and p15 protein expression in both Molt-4 and Nalm-6 cells, as well as p57 protein expression in Nalm-6 cells. Rapamycin additionally decreased mTOR and p70S6K mRNA levels, as well as p70S6K and p-p70S6K protein levels. However, depletion of mTOR by siRNA did not alter the expression and promoter methylation states of p14, p15, and p57. These results indicate that the inhibitory effect of rapamycin may be due mainly to increased p14, p15, and p57 expression via promoter demethylation and decreased mTOR and p70S6K expression in ALL cell lines. These results suggest a potential role for rapamycin in the treatment of adult ALL.
引用
收藏
页码:558 / 568
页数:10
相关论文
共 260 条
  • [1] Kantarjian H(2004)Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia Cancer 101 2788-2801
  • [2] Thomas D(2001)Salvage therapy for refractory or relapsed acute lymphocytic leukemia Hematol Oncol Clin North Am 15 163-205
  • [3] O’Brien S(2006)TOR signaling in growth and metabolism Cell 124 471-484
  • [4] Cortes J(2014)LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway Oncotarget 5 788-801
  • [5] Giles F(2011)Mammalian target of rapamycin as a target in hematological malignancies Target Oncol 6 53-61
  • [6] Jeha S(2004)Upstream and downstream of mTOR Genes Dev 18 1926-1945
  • [7] Garcia-Manero G(2002)The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites J Biol Chem 277 11591-11596
  • [8] Thomas DA(2014)p70 ribosomal protein S6 kinase (Rps6kb1): an update J Clin Pathol 67 1019-1025
  • [9] Wullschleger S(2014)Targeting PI3K/Akt/mTOR signaling in cancer Front Oncol 4 64-2181
  • [10] Loewith R(2006)Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells Mol Cancer Ther 5 2172-285